Immunogenic WT-1 peptides and methods of use thereof
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/00
C07K-007/06
C07K-007/08
출원번호
US-0608964
(2017-05-30)
등록번호
US-10100087
(2018-10-16)
발명자
/ 주소
O'Reilly, Richard J.
Doubrovina, Ekaterina
Selvakumar, Annamalai
출원인 / 주소
Memorial Sloan Kettering Cancer Center
대리인 / 주소
Cohen, Mark S.
인용정보
피인용 횟수 :
0인용 특허 :
54
초록
This invention provides peptides, immunogenic compositions and vaccines, and methods of treating, reducing the incidence of, and inducing immune responses to a WT-1-expressing cancer, comprising peptides derived from the WT-1 protein.
대표청구항▼
1. An isolated WT-1 peptide consisting of an amino acid sequence selected from among AILDFLLLQ (SEQ ID NO:147), RQRPHPGAL (SEQ ID NO:142), GALRNPTAC (SEQ ID NO:143), THSPTHPPR (SEQ ID NO:146), WNQMNLGATLK (SEQ ID NO:173), PGCLQQPEQQG (SEQ ID NO:149), LDFAPPGASAY (SEQ ID NO:156), PLPHFPPSL (SEQ ID NO
1. An isolated WT-1 peptide consisting of an amino acid sequence selected from among AILDFLLLQ (SEQ ID NO:147), RQRPHPGAL (SEQ ID NO:142), GALRNPTAC (SEQ ID NO:143), THSPTHPPR (SEQ ID NO:146), WNQMNLGATLK (SEQ ID NO:173), PGCLQQPEQQG (SEQ ID NO:149), LDFAPPGASAY (SEQ ID NO:156), PLPHFPPSL (SEQ ID NO:144), HFPPSLPPT (SEQ ID NO:145), LLAAILDFL (SEQ ID NO:184), ALRNPTACPL (SEQ ID NO:191), GGCALPVSGA (SEQ ID NO:153), LGATLKGVAA (SEQ ID NO:176), TLGVAAGS (SEQ ID NO:177), KRPFMCAYPGC (SEQ ID NO:180) LKTHTRTHT (SEQ ID NO:182) and SEQ ID NOS:1-15. 2. An isolated WT-1 peptide consisting of 8-30 amino acids comprising an amino acid sequence selected from SEQ ID NO: 142, 143, 144, 145, 146, 147, 149 and 184. 3. The isolated WT-1 peptide of claim 1 or 2, wherein said isolated WT-1 peptide can bind to an HLA class I molecule, an HLA class II molecule, or the combination thereof. 4. A pharmaceutical composition comprising one or more peptides of claim 1 or 2 and a pharmaceutically acceptable carrier, vehicle or excipient. 5. A vaccine comprising (a) one or more isolated WT-1 peptides of claim 1 or 2 and (b) an adjuvant or a carrier. 6. The vaccine of claim 5, wherein said adjuvant is QS21, Freund's incomplete adjuvant, aluminum phosphate, aluminum hydroxide, BCG, alum, a growth factor, a cytokine, a chemokine, an interleukin, Montanide or GM-CSF. 7. The vaccine of claim 5 further comprising a cell population. 8. The vaccine of claim 7 wherein the cell population is selected from lymphocytes, monocytes, macrophages, dendritic cells, endothelial cells, stem cells or any combination thereof. 9. The vaccine of claim 7 wherein the cell population is autologous, syngeneic or allogeneic. 10. The vaccine of claim 7 wherein the population is obtained from peripheral blood, leukopheresis blood product, apheresis blood product, peripheral lymph nodes, gut associated lymphoid tissue, spleen, thymus, cord blood, mesenteric lymph nodes, liver, a site of immunologic lesions, pancreas, cerebrospinal fluid, a tumor sample, or granulomatous tissue. 11. A composition comprising (a) an antigen-presenting cell and (b) one or more peptides of claim 1 or 2. 12. The composition of claim 11 wherein the antigen-presenting cell is a dendritic cell, monocyte, macrophage, cytokine-activated monocyte or an EBV-transformed B-lymphoblastoid cell. 13. The composition of claim 11 wherein the antigen-presenting cell is from a cell line. 14. An isolated WT-1 peptide consisting of 16-30 amino acids comprising an amino acid sequence selected from SEQ ID NO:1-15. 15. A method of treating a subject with a WT-1-expressing cancer or reducing an incidence of a WT-1-expressing cancer, or its relapse, the method comprising administering to said subject one or more peptides of any one of claim 1, 2 or 14, a composition thereof, a composition thereof further comprising an antigen presenting cell, or a vaccine thereof or any combination thereof, thereby treating a subject with a WT-1-expressing cancer, reducing an incidence of a WT-1-expressing cancer or its relapse therein. 16. The method of claim 15, wherein said WT-1-expressing cancer is a leukemia, a desmoplastic small round cell tumor, a gastric cancer, a colon cancer, a lung cancer, a breast cancer, a germ cell tumor, an ovarian cancer, a uterine cancer, a thyroid cancer, a liver cancer, a renal cancer, a Kaposi's sarcoma, a sarcoma, a hepatocellular carcinoma, a Wilms' tumor, an acute myelogenous leukemia (AML), a myelodysplastic syndrome (MDS), mesothelioma or a non-small cell lung cancer (NSCLC). 17. A method of inducing the formation and proliferation of CTL specific for cells of a WT-1-expressing cancer, the method comprising administering to said subject one or more peptides of any one of claim 1, 2 or 14, a composition thereof or a vaccine thereof or any combination thereof, thereby inducing the formation and proliferation of CTL specific for cells of a WT-1-expressing cancer. 18. The method of claim 17, wherein said WT-1-expressing cancer is a leukemia, a desmoplastic small round cell tumor, a gastric cancer, a colon cancer, a lung cancer, a breast cancer, a germ cell tumor, an ovarian cancer, a uterine cancer, a thyroid cancer, a liver cancer, a renal cancer, a Kaposi's sarcoma, a sarcoma, a hepatocellular carcinoma, a Wilms' tumor, an acute myelogenous leukemia (AML), a myelodysplastic syndrome (MDS), mesothelioma or a non-small cell lung cancer (NSCLC). 19. A method of inducing formation and proliferation of (a) a WT1 protein-specific CD8+ lymphocyte; or (b) a CD4+ lymphocyte specific for the WT1 protein, or the combination thereof, the method comprising administering to a subject one or more peptides of any one of claim 1, 2 or 14, a composition thereof, a composition thereof further comprising an antigen presenting cell, or a vaccine thereof, or any combination thereof, thereby inducing formation and proliferation of (a) a WT1 protein-specific CD8+ lymphocyte; or (b) a CD4+ lymphocyte specific for the WT1 protein; or a combination thereof. 20. The method of claim 19, wherein said WT1-expressing cancer is a leukemia, a desmoplastic small round cell tumor, a gastric cancer, a colon cancer, a lung cancer, a breast cancer, a germ cell tumor, an ovarian cancer, a uterine cancer, a thyroid cancer, a liver cancer, a renal cancer, a Kaposi's sarcoma, a sarcoma, a hepatocellular carcinoma, a Wilms' tumor, an acute myelogenous leukemia (AML), a myelodysplastic syndrome (MDS), mesothelioma or a non-small cell lung cancer (NSCLC). 21. A method of inducing formation and proliferation of WT1 protein-specific cytotoxic T lymphocytes comprising contacting a lymphocyte population in vitro or ex vivo with one or more peptides selected from AILDFLLLQ (SEQ ID NO:147), RQRPHPGAL (SEQ ID NO:142), GALRNPTAC (SEQ ID NO:143), THSPTHPPR (SEQ ID NO:146), PGCLQQPEQQG (SEQ ID NO:149), LDFAPPGASAY (SEQ ID NO:156), PLPHFPPSL (SEQ ID NO:144), HFPPSLPPT (SEQ ID NO:145), LLAAILDFL (SEQ ID NO:184), ALRNPTACPL (SEQ ID NO:191), GGCALPVSGA (SEQ ID NO:153), WNQMNLGATLK (SEQ ID NO:173), LGATLKGVAA (SEQ ID NO:176), TLGVAAGS (SEQ ID NO:177), KRPFMCAYPGC (SEQ ID NO:180), LKTHTRTHT (SEQ ID NO:182), and SEQ ID NOS:1-15; or an isolated WT1 peptide consisting of 8-30 amino acids comprising an amino acid sequence selected from SEQ ID NO: 142, 143, 144, 145, 146, 147, 149, and 184; or an isolated WT1 peptide consisting of 16-30 amino acids comprising an amino acid sequence selected from SEQ ID NOS:1-15, a composition thereof, a composition thereof further comprising an antigen presenting cell, or a vaccine thereof, or any combination thereof, thereby inducing formation and proliferation of WT1 protein-specific cytotoxic T lymphocytes. 22. The method of claim 21 wherein the peptide is a pool of peptides having SEQ ID NOS:1-141. 23. A method of treating a subject with a WT1-expressing cancer or reducing an incidence of a WT1-expressing cancer, or its relapse, the method comprising administering to said subject WT1 protein-specific cytotoxic T lymphocytes obtained by the method of claim 21, thereby treating a subject with a WT1-expressing cancer, reducing an incidence of a WT1-expressing cancer or its relapse therein. 24. The method of claim 23 wherein the peptide is a pool of peptides having SEQ ID NOS:1-141. 25. A method of inducing formation and proliferation of (a) a WT1 protein-specific CD8+ lymphocyte; or (b) a CD4+ lymphocyte specific for the WT1 protein, or the combination thereof, the method comprising contacting a lymphocyte population in vitro or ex vivo with one or more peptides selected from AILDFLLLQ (SEQ ID NO:147), RQRPHPGAL (SEQ ID NO:142), GALRNPTAC (SEQ ID NO:143), THSPTHPPR (SEQ ID NO:146), PGCLQQPEQQG (SEQ ID NO:149), LDFAPPGASAY (SEQ ID NO:156), PLPHFPPSL (SEQ ID NO:144), HFPPSLPPT (SEQ ID NO:145), LLAAILDFL (SEQ ID NO:184), ALRNPTACPL (SEQ ID NO:191), GGCALPVSGA (SEQ ID NO:153), WNQMNLGATLK (SEQ ID NO:173), LGATLKGVAA (SEQ ID NO:176), TLGVAAGS (SEQ ID NO:177), KRPFMCAYPGC (SEQ ID NO:180), LKTHTRTHT (SEQ ID NO:182) and SEQ ID NOS:1-15; or an isolated WT1 peptide consisting of 8-30 amino acids comprising an amino acid sequence selected from SEQ ID NO: 142, 143, 144, 145, 146, 147, 149, and 184; or an isolated WT1 peptide consisting of 16-30 amino acids comprising an amino acid sequence selected from SEQ ID NOS:1-15, a composition thereof, a composition thereof further comprising an antigen presenting cell, or a vaccine thereof, or any combination thereof, thereby inducing formation and proliferation of (a) a WT1 protein-specific CD8+ lymphocyte; or (b) a CD4+ lymphocyte specific for the WT1 protein; or a combination thereof. 26. The method of claim 25 wherein the peptides are a pool of peptides having SEQ ID NOS:1-141. 27. A method of treating a subject with a WT1-expressing cancer, the method comprising administering to said subject WT1 protein-specific cytotoxic T lymphocytes obtained by the method of claim 25, thereby treating a subject with a WT1-expressing cancer. 28. The method of any one of claim 21, 23 or 25 wherein the lymphocyte population is obtained from a donor. 29. The method of any one of claim 21, 23 or 25 wherein the lymphocyte population is obtained from a human source. 30. The method of claim 21, 23 or 25, wherein said WT1-expressing cancer is a leukemia, a desmoplastic small round cell tumor, a gastric cancer, a colon cancer, a lung cancer, a breast cancer, a germ cell tumor, an ovarian cancer, a uterine cancer, a thyroid cancer, a liver cancer, a renal cancer, a Kaposi's sarcoma, a sarcoma, a hepatocellular carcinoma, a Wilms' tumor, an acute myelogenous leukemia (AML), a myelodysplastic syndrome (MDS), mesothelioma or a non-small cell lung cancer (NSCLC).
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (54)
Lynch David H. (Bainbridge Island WA), Adoptive immunotherapy with interleukin-7.
Hilton, Traci; Aung, Sandra; van de Ven, Rieneke; Paustian, Christopher; Moudgil, Tarsem; Dubay, Christopher; Twitty, Christopher; Hu, Hong-Ming; Fox, Bernard A., Allogeneic autophagosome-enriched composition for the treatment of disease.
Graddis, Thomas; Laus, Reiner; Diegel, Michael; Vidovic, Damir, Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease.
Gaiger, Alexander; Algate, Paul A.; Mannion, Jane; Clapper, Jonathan David; Wang, Aijun; Ordonez, Nadia; Carter, Lauren; McNeill, Patricia Dianne, Compositions and methods for the detection diagnosis and therapy of hematological malignancies.
Call Katherine M. ; Glaser Thomas M. ; Ito Caryn Y. ; Buckler Alan J. ; Pelletier Jerry,CAX ; Haber Daniel A. ; Rose Elise A. ; Housman David E. ; Breuning Wendy,CAX ; Darveau Andre,CAX, Localization and characterization of the Wilms' tumor gene.
Call Katherine M. ; Glaser Thomas M. ; Ito Caryn Y. ; Buckler Alan J. ; Pelletier Jerry,CAX ; Haber Daniel A. ; Rose Elise A. ; Housman David E. ; Bruening Wendy,CAX ; Darveau Andre,CAX, Localization and characterization of the Wilms' tumor gene.
Dubensky, Jr., Thomas W.; Brockstedt, Dirk G.; Hearst, John E.; Cook, David N., Modified free-living microbes, vaccine compositions and methods of use thereof.
Kang, Chang-Yuil; Ko, Hyun-Jeong; Lee, Jung-Mi; Kim, Yeon-Jeong, Vaccine comprising monocyte or immature myeloid cells (IMC) which were loaded with the ligand of natural killer T cell and antigen.
Herlyn Meenhard (Wynnewood PA) Morris Jennifer (Brookfield WI) Rauscher ; III Frank J. (Cranbury NJ) Rodeck Ulrich (Philadelphia PA), WT1 monoclonal antibodies and methods of use therefor.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.